

Author Relationships With Industry and Other Entities (Comprehensive)—2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease (January 2016)

Committee Member	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Rick Nishimura (<i>Co-Chair</i>)	Mayo Clinic, Division of Cardiovascular Disease—Judd and Mary Morris Leighton Professor of Medicine	None	None	None	None	None	None
Catherine M. Otto (<i>Co-Chair</i>)	University of Washington Division of Cardiology—Professor of Medicine	None	None	None	None	None	None
Robert O. Bonow	Northwestern University Feinberg School of Medicine—Goldberg Distinguished Professor of Cardiology	None	None	None	<ul style="list-style-type: none"> • NHLBI—PROMISE trial (DSMB) • Harvard Clinical Research Institute—DAPT trial (DSMB) 	<ul style="list-style-type: none"> • Gilead • JAMA (Editor) 	None
Blase A. Carabello	East Carolina University, Brody School of Medicine, East Carolina Heart Institute—Chief Cardiology Director	None	None	None	<ul style="list-style-type: none"> • Edwards Lifesciences (DSMB)† 	<ul style="list-style-type: none"> • Medtronic† 	None
John P. Erwin III	Texas A&M College of Medicine, Baylor Scott and White Health—Senior Staff Cardiologist, Clinical Professor and Chair of Internal Medicine	None	None	None	None	<ul style="list-style-type: none"> • DCRI;NIH • Eli Lilly* • TIMI Trialist Group* 	None
Lee Fleisher	University of Pennsylvania, Department of Anesthesiology—Professor of Anesthesiology	<ul style="list-style-type: none"> • Blue Cross/Blue Shield Association—Medical Advisory Panel to the Technology Evaluation Center 	None	None	<ul style="list-style-type: none"> • Johns Hopkins Medical Institutions 	<ul style="list-style-type: none"> • Association of University Anesthesiologists† • Foundation for Anesthesia Education and Research† 	None

		<ul style="list-style-type: none"> • National Quality Forum 					
Hani Jneid	Baylor College of Medicine—Associate Professor of Medicine, Director of Interventional Cardiology Research; The Michael E. DeBakey VA Medical Center—Director of Interventional Cardiology	None	None	None	None	None	None
Michael Mack	The Heart Hospital Baylor Plano—Director					<ul style="list-style-type: none"> • Edwards Lifesciences • Abbott Vascular 	
Chris McLeod	Mayo Clinic, Division of Cardiovascular Disease—Assistant Professor of Medicine	None	None	None	None	None	None
Patrick O’Gara	Brigham and Women’s Hospital—Professor of Medicine; Harvard Medical School—Director of Clinical Cardiology	None	None	None	NIH*	NIH*	None
Vera Rigolin	Northwestern University Feinberg School of Medicine—Professor of Medicine; Northwestern Memorial Hospital—Medical Director, Echocardiography Laboratory	None	None	None	<ul style="list-style-type: none"> • Gilead Sciences • Pfizer 	None	None
Thoralf M. Sundt III	Massachusetts General Hospital—Chief, Division of Cardiac Surgery, Harvard Medical School—Professor of Surgery	None	None	None	<ul style="list-style-type: none"> • Edwards LifeScience—Partner trial (PI) • Medtronic—Perigon trial (PI) 	<ul style="list-style-type: none"> • Thrasos (Steering Committee)* • AATS (Secretary-Elect) 	Defendant, Myocardial protection, 2014
Annemarie Thompson	Duke University Medical Center—Department of Anesthesiology, Professor of Anesthesiology; Residency Program Director	None	None	None	None	None	None

This table represents all relationships of committee members with industry and other entities that were reported by authors, including those not deemed to be relevant to this document, at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

*Significant relationship.

†No financial benefit.

AATS indicates American Associate Thoracic Surgery; ACC, American College of Cardiology; AHA, American Heart Association; CORAL, Cardiovascular Outcomes in Renal Atherosclerotic Lesions; DAPT, dual antiplatelet therapy; DSMB, data safety monitoring board; IMPROVE-IT, Improved Reduction of Outcomes: Vytarin Efficacy International Trial; NHLBI, National Heart, Lung, and Blood Institute; NIH, National Institutes of Health, PROMISE, Prospective Multicenter Imaging Study for Evaluation of Chest Pain; TRANSLATE-ACS, Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome and VA, Veterans Affairs.